PriceTargets.com logo

DENTSPLY SIRONA - XRAY Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $27.91
  • Forecasted Upside: 49.25%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 7 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$18.70 As of 12/20/2024 06:45 PM ET
▲ +0.23 (1.25%)

This chart shows the closing price for XRAY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DENTSPLY SIRONA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XRAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XRAY

Analyst Price Target is $27.91
▲ +49.25% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for DENTSPLY SIRONA in the last 3 months. The average price target is $27.91, with a high forecast of $42.00 and a low forecast of $21.00. The average price target represents a 49.25% upside from the last price of $18.70.

This chart shows the closing price for XRAY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 12 investment analysts is to hold stock in DENTSPLY SIRONA. This rating has held steady since October 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/17/2024Morgan StanleyLower TargetOverweight ➝ Overweight$30.00 ➝ $23.00
12/4/2024MizuhoInitiated CoverageNeutral$21.00
12/3/2024UBS GroupLower TargetBuy ➝ Buy$35.00 ➝ $27.00
11/8/2024Barrington ResearchLower TargetOutperform ➝ Outperform$36.00 ➝ $24.00
11/8/2024Robert W. BairdLower TargetNeutral ➝ Neutral$31.00 ➝ $24.00
11/7/2024Leerink PartnrsDowngradeStrong-Buy ➝ Hold
11/7/2024Leerink PartnersDowngradeOutperform ➝ Market Perform
10/25/2024Needham & Company LLCLower TargetBuy ➝ Buy$34.00 ➝ $29.00
10/8/2024Evercore ISILower TargetOutperform ➝ Outperform$29.00 ➝ $27.00
9/20/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$36.00 ➝ $36.00
8/20/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$34.00 ➝ $34.00
7/31/2024Needham & Company LLCLower TargetBuy ➝ Buy$36.00 ➝ $34.00
7/22/2024Robert W. BairdLower TargetNeutral ➝ Neutral$33.00 ➝ $31.00
7/18/2024Stifel NicolausLower TargetHold ➝ Hold$30.00 ➝ $28.00
7/9/2024Evercore ISILower TargetOutperform ➝ Outperform$28.00 ➝ $27.00
7/8/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$38.00 ➝ $38.00
6/25/2024Evercore ISILower TargetOutperform ➝ Outperform$35.00 ➝ $28.00
5/6/2024The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$34.00 ➝ $30.00
5/3/2024Evercore ISILower TargetOutperform ➝ Outperform$40.00 ➝ $35.00
5/3/2024Barrington ResearchLower TargetOutperform ➝ Outperform$41.00 ➝ $38.00
5/3/2024Piper SandlerReiterated RatingNeutral ➝ Neutral$35.00 ➝ $32.00
5/3/2024Needham & Company LLCLower TargetBuy ➝ Buy$42.00 ➝ $36.00
5/3/2024Robert W. BairdLower TargetNeutral ➝ Neutral$35.00 ➝ $33.00
4/18/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$41.00
3/1/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$41.00
2/29/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00
2/26/2024Leerink PartnrsReiterated RatingOutperform
2/26/2024Leerink PartnersInitiated CoverageOutperform$42.00
1/12/2024Piper SandlerBoost TargetNeutral ➝ Neutral$31.00 ➝ $35.00
1/9/2024Needham & Company LLCBoost TargetBuy ➝ Buy$35.00 ➝ $42.00
11/16/2023Needham & Company LLCInitiated CoverageBuy$35.00
11/13/2023Stifel NicolausLower TargetHold ➝ Hold$35.00 ➝ $32.00
11/10/2023William BlairUpgradeMarket Perform ➝ Outperform
11/7/2023The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$42.00 ➝ $36.00
11/3/2023Barrington ResearchLower TargetOutperform ➝ Outperform$51.00 ➝ $41.00
11/3/2023Morgan StanleyLower TargetOverweight ➝ Overweight$43.00 ➝ $39.00
11/1/2023Stifel NicolausLower TargetHold ➝ Hold$41.00 ➝ $35.00
10/20/2023Morgan StanleyLower TargetOverweight ➝ Overweight$47.00 ➝ $43.00
10/11/2023Evercore ISILower Target$45.00 ➝ $36.00
9/22/2023Piper SandlerLower TargetNeutral ➝ Neutral$42.00 ➝ $39.00
8/4/2023Barrington ResearchReiterated RatingOutperform$51.00
5/5/2023UBS GroupBoost Target$43.00 ➝ $46.00
5/4/2023Stifel NicolausBoost Target$37.00 ➝ $41.00
5/4/2023Barrington ResearchBoost Target$43.00 ➝ $51.00
5/4/2023Robert W. BairdBoost Target$36.00 ➝ $46.00
4/19/2023Morgan StanleyBoost TargetOverweight$39.00 ➝ $45.00
3/1/2023The Goldman Sachs GroupBoost TargetNeutral$34.00 ➝ $39.00
3/1/2023Barrington ResearchBoost Target$40.00 ➝ $43.00
2/6/2023Piper SandlerBoost TargetNeutral$29.00 ➝ $35.00
1/11/2023William BlairUpgradeUnderperform ➝ Market Perform
11/17/2022UBS GroupLower Target$35.00
11/17/2022Evercore ISIBoost Target$34.00
11/17/2022Robert W. BairdLower Target$32.00
11/16/2022The Goldman Sachs GroupLower TargetNeutral$41.00 ➝ $34.00
11/15/2022Barrington ResearchLower Target$51.00 ➝ $40.00
11/15/2022Morgan StanleyLower TargetOverweight$42.00 ➝ $39.00
11/14/2022Piper SandlerLower Target$38.00 ➝ $29.00
11/1/2022William BlairReiterated RatingUnderperform
10/13/2022Morgan StanleyLower TargetOverweight$44.00 ➝ $42.00
8/5/2022William BlairDowngradeMarket Perform ➝ Underperform
7/21/2022The Goldman Sachs GroupLower TargetNeutral$42.00 ➝ $41.00
7/20/2022Morgan StanleyLower TargetOverweight$48.00 ➝ $44.00
7/11/2022Piper SandlerLower Target$41.00 ➝ $38.00
6/1/2022UBS GroupUpgradeNeutral ➝ Buy$58.00 ➝ $47.00
5/11/2022Barrington ResearchLower Target$53.00 ➝ $51.00
4/22/2022HC WainwrightLower TargetHold$58.00 ➝ $48.00
4/21/2022The Goldman Sachs GroupLower TargetNeutral$59.00 ➝ $47.00
4/20/2022Morgan StanleyLower TargetOverweight$62.00 ➝ $52.00
4/20/2022Barrington ResearchLower Target$72.00 ➝ $53.00
4/20/2022Piper SandlerReiterated RatingOverweight ➝ Neutral$71.00 ➝ $46.00
4/19/2022Bank of AmericaDowngradeBuy ➝ Neutral$66.00 ➝ $49.00
4/19/2022William BlairDowngradeOutperform ➝ Market Perform
4/19/2022Robert W. BairdDowngradeOutperform ➝ Neutral$67.00 ➝ $48.00
3/1/2022The Goldman Sachs GroupLower TargetNeutral$66.00 ➝ $59.00
3/1/2022Barrington ResearchLower Target$79.00 ➝ $72.00
3/1/2022Credit Suisse GroupLower TargetOutperform$68.00 ➝ $67.00
3/1/2022HC WainwrightLower Target$66.00 ➝ $58.00
2/18/2022Robert W. BairdLower TargetOutperform$78.00 ➝ $67.00
1/31/2022Morgan StanleyInitiated CoverageOverweight$62.00
8/9/2021HC WainwrightLower TargetNeutral$72.00 ➝ $66.00
8/6/2021Barrington ResearchBoost TargetOutperform$77.00 ➝ $79.00
5/7/2021Barrington ResearchBoost TargetOutperform$71.00 ➝ $77.00
5/7/2021Robert W. BairdBoost TargetOutperform$71.00 ➝ $78.00
5/7/2021HC WainwrightBoost TargetNeutral$60.00 ➝ $72.00
5/6/2021Piper SandlerBoost TargetOverweight$70.00 ➝ $75.00
3/2/2021BarclaysBoost TargetUnderweight$50.00 ➝ $55.00
3/2/2021Robert W. BairdBoost TargetOutperform$62.00 ➝ $71.00
3/2/2021Barrington ResearchUpgradeMarket Perform ➝ Outperform$71.00
3/2/2021HC WainwrightReiterated RatingNeutral$55.00 ➝ $60.00
3/1/2021Piper SandlerBoost TargetOverweight$63.00 ➝ $70.00
1/5/2021Robert W. BairdBoost TargetOutperform$58.00 ➝ $62.00
1/5/2021BarclaysBoost TargetUnderweight$40.00 ➝ $44.00
1/5/2021HC WainwrightBoost TargetNeutral$49.00 ➝ $55.00
12/18/2020Stifel NicolausDowngradeBuy ➝ Hold$52.00
12/15/2020Piper SandlerBoost TargetOverweight$51.00 ➝ $61.00
11/17/2020BarclaysDowngradeEqual Weight ➝ Underweight$40.00
11/9/2020HC WainwrightBoost TargetNeutral$45.00 ➝ $49.00
10/22/2020GuggenheimUpgradeNeutral ➝ Buy
10/5/2020JPMorgan Chase & Co.Boost TargetNeutral$45.00 ➝ $47.00
8/10/2020HC WainwrightLower TargetNeutral$50.00 ➝ $45.00
7/20/2020Bank of AmericaBoost TargetBuy$54.00 ➝ $56.00
6/16/2020Piper SandlerInitiated CoverageOverweight$51.00
6/15/2020HC WainwrightBoost TargetNeutral$38.00 ➝ $50.00
5/27/2020Evercore ISIUpgradeIn-Line ➝ Outperform$50.00
5/14/2020CfraLower TargetHold$53.00 ➝ $38.00
5/11/2020BarclaysLower TargetEqual Weight$42.00 ➝ $40.00
5/11/2020UBS GroupLower TargetNeutral$59.00 ➝ $44.00
5/11/2020Barrington ResearchDowngradeOutperform ➝ Market Perform
4/24/2020HC WainwrightLower TargetNeutral$51.00 ➝ $38.00
4/19/2020Credit Suisse GroupReiterated RatingBuy$50.00
4/19/2020Robert W. BairdUpgradeNeutral ➝ Outperform
4/8/2020Robert W. BairdUpgradeNeutral ➝ Outperform$57.00 ➝ $49.00
4/7/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$58.00 ➝ $40.00
4/2/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$66.00
3/17/2020JPMorgan Chase & Co.Lower TargetNeutral$65.00 ➝ $45.00
3/13/2020Stifel NicolausLower TargetBuy$66.00 ➝ $56.00
3/11/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy
3/3/2020Barrington ResearchLower TargetOutperform$63.00 ➝ $60.00
3/3/2020Robert W. BairdLower TargetNeutral$61.00 ➝ $57.00
3/3/2020HC WainwrightReiterated RatingNeutral$60.00 ➝ $51.00
2/19/2020Stifel NicolausBoost TargetBuy$63.00 ➝ $66.00
1/19/2020BarclaysReiterated RatingHold$64.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 15 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 15 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 15 very positive mentions
  • 4 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 18 very positive mentions
  • 23 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 16 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 15 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 19 very positive mentions
  • 32 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
11/21/2024
  • 27 very positive mentions
  • 80 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 27 very positive mentions
  • 80 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

DENTSPLY SIRONA logo
DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform. It also provides endodontic products consisting of motorized endodontic handpieces, files, sealers, irrigation needles, and other tools that support root canal procedures; restorative products, including dental ceramics, crowns, and veneers; and preventative products, such as curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers, as well as dental anesthetics, prophylaxis paste, dental sealants, and impression materials. In addition, the company offers SureSmile and Byte aligner solutions; VPro/HyperByte, a high-frequency vibration technology device; SureSmile Simulator, which creates a 3D visualization of a patient's outcome; and Byte Plus for treatment planning. Further, it provides dental implants, digital dentures, crown and bridge porcelain products, bone regenerative and restorative solutions, treatment planning software, and educational programs; dental prosthetics; urology catheters; and other health-related consumables. The company serves professional dental and consumable medical device markets through third-party distributors. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina
Read More

Today's Range

Now: $18.70
Low: $18.46
High: $18.84

50 Day Range

MA: $20.72
Low: $17.26
High: $24.73

52 Week Range

Now: $18.70
Low: $17.21
High: $37.60

Volume

10,904,198 shs

Average Volume

3,131,419 shs

Market Capitalization

$3.72 billion

P/E Ratio

N/A

Dividend Yield

3.27%

Beta

0.96

Frequently Asked Questions

What sell-side analysts currently cover shares of DENTSPLY SIRONA?

The following Wall Street research analysts have issued research reports on DENTSPLY SIRONA in the last twelve months: Barrington Research, Evercore ISI, Leerink Partners, Leerink Partnrs, Mizuho, Morgan Stanley, Needham & Company LLC, Piper Sandler, Robert W. Baird, Stifel Nicolaus, StockNews.com, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for XRAY.

What is the current price target for DENTSPLY SIRONA?

0 Wall Street analysts have set twelve-month price targets for DENTSPLY SIRONA in the last year. Their average twelve-month price target is $27.91, suggesting a possible upside of 49.2%. Leerink Partners has the highest price target set, predicting XRAY will reach $42.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $21.00 for DENTSPLY SIRONA in the next year.
View the latest price targets for XRAY.

What is the current consensus analyst rating for DENTSPLY SIRONA?

DENTSPLY SIRONA currently has 7 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in XRAY, but not buy more shares or sell existing shares.
View the latest ratings for XRAY.

What other companies compete with DENTSPLY SIRONA?

Other companies that are similar to DENTSPLY SIRONA include Merit Medical Systems, Haemonetics, ICU Medical, QuidelOrtho and Neogen. Learn More about companies similar to DENTSPLY SIRONA.

How do I contact DENTSPLY SIRONA's investor relations team?

DENTSPLY SIRONA's physical mailing address is 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC, 28277. The medical instruments supplier's listed phone number is (844) 848-0137 and its investor relations email address is [email protected]. The official website for DENTSPLY SIRONA is www.dentsplysirona.com. Learn More about contacing DENTSPLY SIRONA investor relations.